Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
10:31pm, Wednesday, 25'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing
Vir Biotechnology Announces Proposed Public Offering of Common Stock
04:05pm, Tuesday, 24'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
01:30pm, Tuesday, 24'th Feb 2026
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at hi
These Analysts Boost Their Forecasts On Vir Biotechnology
01:05pm, Tuesday, 24'th Feb 2026
Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.
U.S. stock futures rose on Tuesday after closing lower on Monday. Futures of all the major benchmark indices were positive following a sell-off.
What's Happening With VIR Stock?
04:10am, Tuesday, 24'th Feb 2026
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging P
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
02:04am, Tuesday, 24'th Feb 2026
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
09:56pm, Monday, 23'rd Feb 2026
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago.
Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas
07:13pm, Monday, 23'rd Feb 2026
Vir stock catapulted late Monday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
05:14pm, Monday, 23'rd Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. �
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targetin
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechn
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Monday, 09'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate u
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.00 Consensus Price Target from Brokerages
01:18am, Monday, 26'th Jan 2026
Shares of Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the company, Marketbeat.co
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:25am, Thursday, 15'th Jan 2026
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
